BiomX (NYSEAMERICAN:PHGE) Trading 10.5% Higher – Here’s Why

Shares of BiomX Inc. (NYSEAMERICAN:PHGE) traded up 10.5% during mid-day trading on Friday . The company traded as high as $0.9861 and last traded at $0.8165. 12,371,591 shares changed hands during trading, a decline of 3% from the average session volume of 12,752,066 shares. The stock had previously closed at $0.7389.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered BiomX from a “buy” rating to a “hold” rating in a report on Monday, March 9th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, BiomX has a consensus rating of “Hold” and a consensus target price of $26.00.

BiomX Stock Performance

The firm’s 50-day simple moving average is $2.50 and its 200 day simple moving average is $3.79. The stock has a market capitalization of $1.30 million, a P/E ratio of -0.25 and a beta of 1.02.

BiomX (NYSEAMERICAN:PHGE) last announced its quarterly earnings data on Thursday, February 19th. The company reported $6.99 earnings per share for the quarter. As a group, research analysts expect that BiomX Inc. will post -5.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other BiomX news, Director Reuven Yeganeh sold 530,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $5.00, for a total transaction of $2,650,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 21.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BiomX

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC bought a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned about 0.61% of BiomX at the end of the most recent quarter. Institutional investors own 40.57% of the company’s stock.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.